Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02), Zacks reports.
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies stock traded up $0.34 during mid-day trading on Tuesday, hitting $6.71. 2,906,729 shares of the company’s stock traded hands, compared to its average volume of 2,868,341. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a one year low of $2.69 and a one year high of $7.30. The firm has a 50 day moving average price of $6.06 and a 200 day moving average price of $5.45. The company has a market cap of $1.93 billion, a PE ratio of -17.65 and a beta of 1.22.
Analysts Set New Price Targets
TSHA has been the subject of a number of research reports. The Goldman Sachs Group lifted their target price on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Pivotal Research set a $14.00 price target on Taysha Gene Therapies in a report on Tuesday, June 23rd. Bank of America upped their price objective on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and an average target price of $12.77.
Insider Activity at Taysha Gene Therapies
In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.
Hedge Funds Weigh In On Taysha Gene Therapies
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marex Group plc acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $31,000. Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after acquiring an additional 6,350 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after acquiring an additional 4,607 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Read More
- Five stocks we like better than Taysha Gene Therapies
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
